Answers are grounded in this paper and cite their sources.
In patients with AIS undergoing ET, tirofiban is not associated with higher sICH, it seems to lead to lower odds of deaths and better odds of long-term functional independence. Further investigations are needed to determine the efficacy of tirofiban in preventing early reocclusion, the underlying mechanisms, and its optimal treatment protocol.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: